1
|
Tang Z, Sun Y, Harley SE, Zou H and Yu H:
Human Bub1 protects centromeric sister-chromatid cohesion through
Shugoshin during mitosis. Proc Natl Acad Sci USA. 101:18012–18017.
2004. View Article : Google Scholar : PubMed/NCBI
|
2
|
Yu H: Regulation of APC-Cdc20 by the
spindle checkpoint. Curr Opin Cell Biol. 14:706–714. 2002.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Nasmyth K: Segregating sister genomes: the
molecular biology of chromosome separation. Science. 297:559–565.
2002. View Article : Google Scholar : PubMed/NCBI
|
4
|
Cleveland DW, Mao Y and Sullivan KF:
Centromeres and kinetochores: from epigenetics to mitotic
checkpoint signaling. Cell. 112:407–421. 2003. View Article : Google Scholar : PubMed/NCBI
|
5
|
Tang Z, Shu H, Oncel D, et al:
Phosphorylation of Cdc20 by Bub1 provides a catalytic mechanism for
APC/C inhibition by the spindle checkpoint. Mol Cell. 16:387–397.
2004. View Article : Google Scholar : PubMed/NCBI
|
6
|
Genther Williams SM, Disbrow GL, Schlegel
R, et al: Requirement of epidermal growth factor receptor for
hyperplasia induced by E5, a high-risk human papillomavirus
oncogene. Cancer Res. 65:6534–6542. 2005.PubMed/NCBI
|
7
|
Burgert HG, Ruzsics Z, Obermeier S, et al:
A subversion of host defense mechanisms by adenoviruses. Curr Top
Microbiol Immunol. 269:273–318. 2002.PubMed/NCBI
|
8
|
Vazquez-Ortiz G, Ciudad CJ, Pina P, et al:
Gene identification by cDNA arrays in HPV-positive cervical cancer.
Arch Med Res. 36:448–458. 2005. View Article : Google Scholar : PubMed/NCBI
|
9
|
Medema RH, Klompmaker R, Smits VA and
Rijksen G: P21waf1 can block cells at two points in the cell cycle,
but does not interfere with processive DNA replication or
stress-activated kinases. Oncogene. 16:431–441. 1998. View Article : Google Scholar : PubMed/NCBI
|
10
|
Freitas S, Moore DH, Michael H and Kelley
MR: Studies of apurinic/apyrimidinic endonuclease/ref21 expression
in epithelial ovarian cancer: correlations with tumor progression
and platinum resistance. Clin Cancer Res. 9:4689–4694.
2003.PubMed/NCBI
|
11
|
Kozak M: At least six nucleotides
preceding the AUG initiator codon enhance translation in mammalian
cells. J Mol Biol. 196:947–950. 1987. View Article : Google Scholar : PubMed/NCBI
|
12
|
Biswas C, Kell B, Mant C, et al: Detection
of human papillomavirus type 16 early-gene transcription by reverse
transcription-PCR is associated with abnormal cervical cytology. J
Clin Microbiol. 35:1560–1564. 1997.PubMed/NCBI
|
13
|
Winer J, Jung CK, Shackel I and Williams
PM: Development and validation of real-time quantitative reverse
transcriptase-polymerase chain reaction for monitoring gene
expression in cardiac myocytes in vitro. Anal Biochem. 270:41–49.
1999. View Article : Google Scholar
|
14
|
Krawczyk E, Suprynowicz FA, Sudarshan SR
and Schlegel R: Membrane orientation of the human papillomavirus
type 16 E5 oncoprotein. J Virol. 84:1696–1703. 2010. View Article : Google Scholar : PubMed/NCBI
|
15
|
Scholzen T and Gerdes J: The Ki-67
protein: from the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
16
|
Gao P and Zheng J: High-risk HPV
E5-induced cell fusion: a critical initiating event in the early
stage of HPV-associated cervical cancer. J Virol. 7:238–240. 2010.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Boulenouar S, Weyn C, Van Noppen M, et al:
Effects of HPV-16 E5, E6 and E7 proteins on survival, adhesion,
migration and invasion of trophoblastic cells. Carcinogenesis.
31:473–480. 2010. View Article : Google Scholar : PubMed/NCBI
|
18
|
Pedroza-Saavedra A, Lam EW,
Esquivel-Guadarrama F and Gutierrez-Xicotencatl L: The human
papillomavirus type 16 E5 oncoprotein synergizes with EGF-receptor
signaling to enhance cell cycle progression and the down-regulation
of p27(Kip1). Virology. 400:44–52. 2010. View Article : Google Scholar : PubMed/NCBI
|
19
|
Kivi N, Greco D, Auvinen P and Auvinen E:
Genes involved in cell adhesion, cell motility and mitogenic
signaling are altered due to HPV 16 E5 protein expression.
Oncogene. 27:2532–2541. 2008. View Article : Google Scholar : PubMed/NCBI
|
20
|
Nath R, Mant CA, Kell B, et al: Analyses
of variant human papillomavirus type-16 E5 proteins for their
ability to induce mitogenesis of murine fibroblasts. Cancer Cell
Int. 6:192006. View Article : Google Scholar : PubMed/NCBI
|
21
|
Kim MK, Kim HS, Kim SH, et al: Human
papillomavirus type 16 E5 oncoprotein as a new target for cervical
cancer treatment. Biochem Pharmacol. 80:1930–1935. 2010. View Article : Google Scholar : PubMed/NCBI
|
22
|
Ruesch MN and Laimins LA: Initiation of
DNA synthesis by human papillomavirus E7 oncoproteins is resistant
to p21-mediated inhibition of cyclin E-cdk2 activity. J Virol.
71:5570–5578. 1997.PubMed/NCBI
|
23
|
Tsao YP, Li LY, Tsai TC and Chen SL: Human
papillomavirus type 11 and 16 E5 represses p21 (WafI/SdiI/CipI)
gene expression in fibroblasts and keratinocytes. J Virol.
70:7535–7539. 1996.PubMed/NCBI
|
24
|
Defeo-Jones D, Vuocolo GA, Haskell KM, et
al: Papillomavirus E7 protein binding to the retinoblastoma protein
is not required for viral induction of warts. J Virol. 67:716–725.
1993.PubMed/NCBI
|
25
|
Maufort JP, Shai A, Pitot HC and Lambert
PF: A role for HPV16 E5 in cervical carcinogenesis. Cancer Res.
70:2924–2931. 2010. View Article : Google Scholar : PubMed/NCBI
|